RESULTS OF SURGICAL TREATMENT OF GASTRIC CARCINOMA OF LOWER THIRD AT THAI BINH PROVINCE GENERAL HOSPITAL

Tùng Lâm Phạm 1, Văn Vụ Kim 1,2,
1 HMU
2 K hospital

Main Article Content

Abstract

Objectives: To describe clinical, paraclinical characteristics and surgical results of lower third gastric carcinoma at Thai Binh province general hospital. Methods: Including 143 patients with carcinoma of the lower third of the stomach who were surgically treated at Thai Binh Provincial General Hospital from January 1, 2019 to January 1, 2021. Results: Mean age: 64.9 ± 10 (35-89 years old); male/female ratio = 2.18/1; The time from symptom onset to hospital admission was mainly 6-12 months (46.2%), common clinical symptoms: epigastric abdominal pain (74.1%), anorexia and weight loss (55 .6%), vomiting (39.2%), pyloric stenosis (16.1%), asymptomatic (7%); 30.1% had a history of chronic gastric ulcer. Macroscopic images are mainly ulcerative and invasive ulceration (88.1%), wart and infiltrative form 4.9% and 7%, respectively. Histopathology: moderately differentiated adenocarcinoma (44.7%), poorly differentiated adenocarcinoma (30.9%), highly differentiated adenocarcinoma (5.6%), ring cell carcinoma (13.9%), cancer of the mucous gland (4.9%). Most tumor invasion was T4 (45.5%), T1, T2 (30.1%); 60.1% of patients had lymph node metastasis, the average number of removed lymph nodes was 11.57 ± 4.8; the average number of metastatic lymph nodes was 3.71 ± 4.5 lymph nodes. In terms of surgical results, time to have a bowel movement: 3.85 ± 0.84 days, time to drain: 7.1 ± 1.3 days, hospital stay: 9.6 ± 2.1 days; Post-operative complications were 8.4%, of which the most common were pneumonia 2.8%, wound infection 2.8%, postoperative bleeding 1.4%, anastomosis and incisional tear 0.7. %. 3 patients having surgery again accounted for 2.1%, 2 cases of postoperative bleeding and 1 case of incision; 97.9% of stable patients were discharged, 2.1% of patients died or seriously transferred to hospital. Overall survival was 40 ± 1.5 months, disease-free survival time was 38.8 ± 1.6 months. Conclusion: Lower third gastric carcinoma occurs at different ages, moderate progression, histopathology is usually medium-differentiated adenocarcinoma, usually in the locally invasive stage, the rate is low. high rate of lymph node metastasis. Surgical treatment of carcinoma of the lower third of the stomach is relatively safe, feasible and has few complications.

Article Details

References

1. Nguyễn Khánh Toàn. Đánh giá kết quả hoá trị triệu chứng phác đồ XELOX cho Ung thư dạ dày giai đoạn muộn. Published online 2013.
2. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46. doi:10.1056/NEJMoa073149
3. Trịnh Hồng Sơn. Nghiên cứu nạo vét hạch trong điều trị phẫu thuật ung thư dạ dày 2001 — LUẬN ÁN TIẾN SĨ - Cơ sở dữ liệu toàn văn. Published 2001. Accessed April 24, 2023. http:// luanan.nlv.gov.vn/ luanan?a=d&d=TTbFfqzJwpoO2001.1.26
4. Nguyễn Lam Hòa. Nghiên cứu đặc điểm lâm sàng, giải phẫu bệnh, kết quả điều trị phẫu thuật ung thư dạ dày và hóa chất bổ trợ tại bệnh viện Việt Tiệp Hải Phòng. Published online 2008.
5. Nguyễn Trọng Đạt, Nguyễn Hoàng Minh, Nguyễn Văn Trọng, Bùi Long. Kết quả sớm phẫu thuật triệt căn điều trị ung thư biểu mô dạ dày ở bệnh nhân dưới 40 tuổi tại bệnh viện K. Tạp Chí Học Việt Nam. 2023;523(2). doi:10.51298/vmj.v523i2.4491
6. Nguyễn Văn Thưởng. Đánh giá kết quả phẫu thuật nội soi điều trị ung thư biểu mô dạ dày giai đoạn tiến triển tại bệnh viện Việt Đức. Published online 2015.
7. Đặng Quốc Ái, Trịnh Lê Huy. Đánh giá kết quả phẫu thuật nội soi kết hợp hóa chất trị liệu trong điều trị ung thư biểu mô dạ dày. Tạp Chí Học Việt Nam. 2023;524(2). doi:10.51298/vmj.v524i2.4894
8. Đặng Quốc Ái, Vũ Khang Ninh. Phẫu thuật nội soi cắt bán phần cực dưới dạ dày điều trị ung thư biểu mô dạ dày một nghiên cứu hồi cứu đa trung tâm. Tạp Chí Học Việt Nam. 2023;524(1B). doi:10.51298/vmj.v524i1B.4782
9. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet Lond Engl. 2012; 379(9813): 315-321. doi:10.1016/ S0140-6736(11)61873-4